On the eve of the final year of President Ma Ying-jeou’s (馬英九) second four-year term today, Ma’s disapproval rating stood at nearly 70 percent or higher in various surveys, while his approval rating was as low as less than 20 percent.
About 68.4 percent of respondents were dissatisfied with Ma’s performance as president, against 21.3 percent who said they were satisfied, in a telephone-based poll conducted on Sunday, Taiwan Thinktank said yesterday.
A cross-analysis of differences in political party affiliation found that among respondents who identified themselves as supporters of the pan-blue camp, 50.5 percent said they found Ma’s governance dissatisfactory, the poll showed.
Photo: Chen Chih-chu, Taipei Times
The survey found 49.1 percent of respondents doubted the image Ma has sought to establish as a clean politician because they said they believed there might have been some irregularities involving Ma in his handling of the Taipei Dome project when he was Taipei mayor, while 29.2 percent believed he was clean.
The president has repeatedly stressed that only by respecting the so-called “1992 consensus” — an alleged agreement between the Chinese Nationalist Party (KMT) and the Chinese Communist Party that there is “one China, with each side having its own interpretation of what ‘one China’” means” — can the “status quo” be maintained, but the survey found that a majority of people did not agree.
According to the survey, 68.7 percent of the public said they support maintaining the “status quo,” while only 15.4 percent said they support the “1992 consensus.”
KMT Chairman and New Taipei City Mayor Eric Chu’s (朱立倫) description of cross-strait relations as “both sides belonging to one China,” to which Ma has given his endorsement, was supported by only 13 percent of respondents, while 77.4 percent said Taiwan and China are both sovereign states, independent of each other and not subordinate to the other, the survey found.
About 50.2 percent of respondents said the government should place more consideration on the impact of cross-strait exchanges and negotiations on national security, while 38.1 percent said economic benefits should be the main concern, the poll showed.
On a scale of zero to 10, with zero indicating “not at all” and 10 signifying “extremely,” the extent to which respondents perceived Taiwan as depending on China to maintain its economic growth stood at 6.1. Moreover, 62.2 percent of respondents said Taiwan should deepen its economic ties with countries other than China.
A survey that the Chinese-language Liberty Times (the sister paper of the Taipei Times) conducted from Saturday to Monday found that 14.52 percent of respondents said they were satisfied with Ma’s performance over the past seven years, against 64.3 percent who thought the opposite.
Similar results were found in a survey released by the TVBS poll center yesterday showing Ma’s approval rating at 16 percent and disapproval rating at 67 percent.
In another poll, conducted by Taiwan Indicators Survey Research, 15.4 percent expressed satisfaction with Ma, while 75.7 percent were dissatisfied.
Additional reporting by Shih Hsiu-chuan
BREAKING RECORDS: Kuo Hsing-chun’s snatch, clean and jerk, and combined lifts were all Olympic records, although well off her combined world record Taiwanese weightlifter Kuo Hsing-chun (郭婞淳) yesterday completed her elusive quest for Olympic gold, clinching Taiwan’s first win at the Tokyo Games as she set Olympic records in the women’s under-59kg weight class. Kuo, who has not lost a major competition in her weight class since the 2016 Olympics in Rio de Janeiro, where she was hampered by injury and finished third, finally chased down the gold medal that had long remained just out of her grasp. The 27-year-old finished with a combined lift of 236kg — 103kg in the snatch and 133kg in the clean and jerk — 21kg more
A TAIWAN FIRST: The duo are the first badminton players from Taiwan to climb an Olympic podium, and Tai Tzu-ying has a shot at doing the same today Taiwanese badminton duo Lee Yang (李洋) and Wang Chi-lin (王齊麟) yesterday won the nation’s first Olympic gold medal in the sport when they prevailed over a third-seeded Chinese pair in the final of the men’s doubles at the Tokyo Olympics. Lee and Wang, both first-time Olympians, defeated Liu Yuchen (劉雨辰) and Li Junhui (李俊慧) 21-18, 21-12 in a 34-minute final at the Musashino Forest Sports Plaza. As of yesterday, Taiwan had bagged seven medals in Tokyo — two golds, two silvers and three bronzes — topping its previous best of five medals in 2000 and 2004. Taiwan moved to No. 17 in the
NO ‘ONE CHINA’ LIE: The appropriations act passed the US House of Representatives with a vote of 217-212, but still needs Senate approval and the president’s signature The US House of Representatives on Wednesday passed a foreign assistance spending bill with an amendment forbidding that funds be used to create, procure or display maps depicting Taiwan as part of the People’s Republic of China. The amendment was introduced by five Republican representatives — Tom Tiffany, Steve Chabot, Scott Perry, Kat Cammack and Mike Gallagher — and passed unanimously in a bundle with a dozen other amendments. “This is a common sense measure,” Tiffany said, speaking on the House floor on Wednesday. “As we all know, Taiwan has never been part of communist China. The Taiwanese people elect their
THE HOME TEAM: DPP Legislator Kao Chia-yu said she canceled her booking for an AstraZeneca shot as soon as she heard that the Medigen vaccine was an option President Tsai Ing-wen (蔡英文) yesterday said that she would get inoculated with the COVID-19 vaccine manufactured by Taiwan-based Medigen Vaccine Biologics Corp (高端疫苗). Tsai wrote on Facebook that she had registered for her first vaccine dose using the national online COVID-19 vaccination booking system, which allows people to indicate their preferred vaccine brand and to make an appointment when the shot becomes available. Tsai said that she opted for the Medigen vaccine — one of three now available on the system, along with the AstraZeneca and Moderna vaccines — even though Medigen has yet to deliver any doses or provide a